Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 13/20 | 0.44 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.39 |
| ▸ | PDE4A | P27815 | 2/20 | 0.39 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.39 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.39 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.39 |
| ▸ | JAK3 | P52333 | 1/20 | 0.37 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.37 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.37 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1610010 | 0.90 | PDE10A (0.44) | PDE10AJAK3ADORA2A | |
| SCHEMBL1609959 | 0.89 | PDE10A (0.41) | PDE10ACHRM3PDE4APDE4BPDE4C | |
| SCHEMBL1609910 | 0.80 | PDE10A (0.42) | PDE10A | |
| SCHEMBL1611084 | 0.80 | PDE10A (0.60) | PDE10ACHRM3PDE4APDE4BPDE4C | |
| SCHEMBL1609892 | 0.79 | PDE10A (0.54) | PDE10ACHRM3PDE4APDE4BPDE4C | |
| SCHEMBL1611392 | 0.79 | PDE10A (0.44) | PDE10ACHRM3PDE4APDE4BPDE4C | |
| SCHEMBL1609883 | 0.77 | PDE10A (0.43) | PDE10ACHRM3PDE4APDE4BPDE4C | |
| SCHEMBL1610317 | 0.75 | SMN1; SMN2 (0.42) | PDE10A | |
| SCHEMBL1609122 | 0.75 | PDE10A (0.48) | PDE10ACHRM3PDE4APDE4BPDE4C | |
| SCHEMBL13769420 | 0.75 | MTNR1A (0.41) | PDE10ACHRM3PDE4APDE4BPDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110086759-A1 | CHEMICAL COMPOUNDS | SYNGENTA CROP PROTECTION, INC. (US) | 2011-04-14 | — | — | US | disclosed |
| US-20110086759-A1 | CHEMICAL COMPOUNDS | SYNGENTA CROP PROTECTION, INC. (US) | 2011-04-14 | — | — | US | disclosed |
| US-20110086759-A1 | CHEMICAL COMPOUNDS | SYNGENTA CROP PROTECTION, INC. (US) | 2011-04-14 | — | — | US | disclosed |
| WO-2009081112-A2 | CHEMICAL COMPOUNDS | SYNGENTA LIMITED (GB) | 2009-07-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110086759-A1 | CHEMICAL COMPOUNDS | DDT, PNPO, CBR3 | PDE10A 1704/4885CHRM3 2705/4885PDE4A 1115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.